Financials in USD. Standardized financial statements.
A compact view of how AIM ImmunoTech Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $88,000 | $170,000 | $202,000 | $141,000 | $135,000 | $163,000 | $140,000 | $367,000 | $437,000 | $92,000 |
| Revenue Growth? | -48.2% | -15.8% | +43.3% | +4.4% | -17.2% | +16.4% | -61.9% | -16.0% | +375.0% | 0.0% |
| Cost of Revenue? | $338,000 | $31,000 | $42,000 | $0 | $850,000 | $806,000 | $893,000 | $884,000 | $1.18M | $1.11M |
| Gross Profit? | -$250,000 | $139,000 | $160,000 | $141,000 | -$715,000 | -$643,000 | -$753,000 | -$517,000 | -$746,000 | -$1.02M |
| Gross Margin? | -284.1% | +81.8% | +79.2% | +100.0% | -529.6% | -394.5% | -537.9% | -140.9% | -170.7% | -1104.3% |
| Operating Expenses? | $10.28M | $19.91M | $32.08M | $20.06M | $18.12M | $14.51M | $11.69M | $10.98M | $10.67M | $12.79M |
| Operating Income? | -$10.53M | -$19.77M | -$31.92M | -$19.92M | -$18.84M | -$15.15M | -$12.44M | -$11.50M | -$11.42M | -$13.80M |
| EBITDA? | -$10.32M | -$16.49M | -$28.72M | -$19.87M | -$18.29M | -$12.99M | -$8.15M | -$8.40M | -$7.12M | -$6.33M |
| Income Before Tax | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M | -$14.40M | -$9.40M | -$9.81M | -$8.26M | -$7.50M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.19M | $0 | $0 |
| Net Income? | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M | -$14.40M | -$9.40M | -$9.81M | -$8.26M | -$7.50M |
| EPS? | $-8.62 | $-11.22 | $-21.64 | $-14.69 | $-14.67 | $-16.41 | $-93.71 | $-355.19 | $-463.19 | $-543.05 |
| Diluted EPS? | $-8.62 | $-11.22 | $-21.64 | $-14.69 | $-14.67 | $-16.41 | $-93.71 | $-355.19 | $-463.19 | $-543.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality